GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Debt-to-Asset

CollPlant Biotechnologies (CollPlant Biotechnologies) Debt-to-Asset : 0.09 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Debt-to-Asset?

CollPlant Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.62 Mil. CollPlant Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.54 Mil. CollPlant Biotechnologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $34.13 Mil. CollPlant Biotechnologies's debt to asset for the quarter that ended in Dec. 2023 was 0.09.


CollPlant Biotechnologies Debt-to-Asset Historical Data

The historical data trend for CollPlant Biotechnologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Debt-to-Asset Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.31 0.07 0.08 0.09

CollPlant Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.10 0.08 0.08 0.09

Competitive Comparison of CollPlant Biotechnologies's Debt-to-Asset

For the Biotechnology subindustry, CollPlant Biotechnologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Debt-to-Asset falls into.



CollPlant Biotechnologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CollPlant Biotechnologies's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

CollPlant Biotechnologies's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CollPlant Biotechnologies  (NAS:CLGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


CollPlant Biotechnologies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.